Related Experiment Video
Updated: Aug 6, 2026

A Method for Murine Islet Isolation and Subcapsular Kidney Transplantation
Published on: April 13, 2011
The effectiveness of different treatment options for non-islet cell tumour hypoglycaemia
1Supraregional Hormone Centre, Clinical Laboratory, Royal Surrey County Hospital, Guildford, Surrey, UK. dteale@royalsurrey.nhs.uk
Objective:
To compare the outcome of different treatment options used in several cases of non-islet cell tumour hypoglycaemia (NICTH).
Patients:
Eight cases of NICTH were referred for diagnosis and monitoring following either surgical or medical treatment.
Methods:
Serum samples collected throughout the time-course of each case were analysed for glucose, insulin, C-peptide, IGF-I, total IGF-II, total IGF-II to IGF-I ratio and, in most of the cases, big IGF-II.
Results:
Surgical excision was successful in the relief of symptoms and normalization of the biochemical parameters. Therapeutic treatment with glucocorticoids confirmed previous studies showing the suppressive effect on tumour (big) IGF-II production. The present data show that the effect was dose-dependent and reversible if doses were below a critical level.
Conclusions:
Within the limits of the cases studied, and the time-scales involved, moderate- to high-dose glucocorticoid therapy had immediate beneficial influence on symptomatic hypoglycaemia and, if tolerated in the long term, was effective in correcting the underlying biochemical dysfunction, unlike other therapeutic regimens. This effectiveness was only achieved when the dose exceeded a threshold level specific to the patient. In addition, reduction of the dose or withdrawal of the drug caused a return of the abnormal biochemical profile. Surgical removal of the malignancy, where this was an option, was successful within the periods studied.
Related Concept Videos
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Oral Hypoglycemic Agents: Glinides
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors
Hypoglycemia and Glucagon

